Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Current Leases (2019 - 2023)

ADC Therapeutics has reported Current Leases over the past 5 years, most recently at $1.5 million for Q4 2023.

  • Quarterly results put Current Leases at $1.5 million for Q4 2023, up 33.73% from a year ago — trailing twelve months through Dec 2023 was $1.5 million (up 33.73% YoY), and the annual figure for FY2023 was $1.5 million, up 33.73%.
  • Current Leases reached $1.5 million in Q4 2023 per ADCT's latest filing, up from $1.4 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.6 million in Q2 2023 and bottomed at $1002.0 in Q4 2020.
  • Median Current Leases over the past 5 years was $952500.0 (2019), compared with a mean of $846636.3.
  • The largest annual shift saw Current Leases plummeted 99.89% in 2020 before it soared 106508.36% in 2022.
  • Over 5 years, Current Leases stood at $924000.0 in 2019, then tumbled by 99.89% to $1002.0 in 2020, then rose by 2.69% to $1029.0 in 2021, then skyrocketed by 106508.36% to $1.1 million in 2022, then soared by 33.73% to $1.5 million in 2023.
  • Business Quant data shows Current Leases for ADCT at $1.5 million in Q4 2023, $1.4 million in Q3 2023, and $1.6 million in Q2 2023.